HDAC9 and breast carcinoma: In tumors with low SLFN11 expression, such as ovarian cancer, breast cancer, colorectal cancer, small - cell lung cancer, and bladder cancer, combine chemotherapy with HDAC inhibitors or demethylating agents to verify whether they can enhance chemotherapy sensitivity by upregulating SLFN11.